TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01913119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2
Study: NCT00235040

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smart Form
Description: Computer Decision Support System

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Smart Form
Description: Computer Decision Support System
Study: NCT00544440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Study: NCT03961971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT04527432

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Survey at baseline, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-CoV-2 antibody test
Description: SARS-CoV-2 antibody test results and testing again at 6 and 12 months
Study: NCT00544440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablet taken orally twice daily
Study: NCT01740817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: 30 ml/h for 48 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: 30 ml/h for 48 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30 ml/h for 48 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30 ml/h for 48 h
Study: NCT02533206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Polypectomy Performed in Clinic
Description: Endoscopic polypectomy performed in clinic under local and topical anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery (FESS)
Description: Functional Endoscopic Sinus Surgery
Study: NCT00444613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 (mecobalamin)
Description: Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 (mecobalamin)
Description: Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, placebo twice a week for 3.5 years.
Study: NCT03724838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole with Sildenafil Citrate
Description: Patients will take esomeprazole single dose of 40 mg orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole with Sildenafil Citrate
Description: Patients will take esomeprazole single dose of 40 mg orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Patients will take Sildenafil Citrate 40mg every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Esomeprazole
Description: Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
Study: NCT02347319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pennel
Description: Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Legalon
Description: Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
Study: NCT02001051

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adrenalectomy
Description: Surgery to remove tumor when enrolled in the protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation for 6 months prior to surgery
Study: NCT00062101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given PO
Study: NCT03724838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sildenafil Citrate
Description: Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
Study: NCT00062101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01221831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P 1 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P 1 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P2 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estetrol, P2 and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate, dienogest and placebo tablets
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day
Study: NCT03724838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sildenafil Citrate
Description: Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
Study: NCT05886231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music sound therapy
Description: investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
Study: NCT00937846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1034702
Description: Single oral 5 mg dose in liquid formulation
Study: NCT02114749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a set of wearable respiration and cardiac monitoring devices
Description: feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
Study: NCT02999048

Intervention type: DRUG
Group type: OTHER
Intervention: Panax Notoginseng Saponins
Description: Panax Notoginseng Saponins integrated with conventional therapy
Study: NCT01844141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70% alcohol
Description: After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
Study: NCT03241316

Intervention type: BEHAVIORAL
Intervention: Observational study of behaviour
Description: As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.

Intervention type: BEHAVIORAL
Intervention: Observational study of behaviour
Description: As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
Study: NCT01754987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid + Sorafenib

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Study: NCT04235257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
Study: NCT04474431

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
Description: Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
Study: NCT02033135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with Zilver PTX
Description: Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
Study: NCT01844141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% alcohol - 0.5% clorhexidine
Description: In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
Study: NCT02139449

Intervention type: PROCEDURE
Intervention: ICD/CRT
Description: cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
Study: NCT02033135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX
Study: NCT03710317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: 100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
Study: NCT02435199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 600mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02777099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic postconditioning
Description: Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
Study: NCT00744393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate
Description: The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
Study: NCT02205762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Stratum I
Study: NCT02537106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.5% NaCl
Description: After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3% NaCl
Description: After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
Study: NCT02205762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Stratum I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDOMETHACIN
Description: Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: fixed dose weekly orally for total treatment duration of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation (RIC-HSCT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Study: NCT02246816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Description: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Study: NCT02655367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaked oats
Description: Test meal consisting of 264g porridge made with flaked oats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaked oats
Description: Test meal consisting of 264g porridge made with flaked oats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milled oats
Description: Test meal consisting of 264g porridge made with milled oats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milled oats
Description: Test meal consisting of 264g porridge made with milled oats
Study: NCT02865733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
Study: NCT01852019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.
Study: NCT02196818

Intervention type: DEVICE
Intervention: Mpact Acetabular Shell
Description: Total Hip Replacement
Study: NCT04314830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training with perturbations
Description: Changes in speed of one of the belt of the split belt treadmill during swing phase

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without perturbation
Description: Walking on a treadmill with steady belt speed
Study: NCT04980261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF + autograft
Description: Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
Study: NCT00372190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensionfree vaginal mesh kit (Prolift)
Description: Insertion of a tension free vaginal mesh using a Prolift mesh kit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic vaginal prolapse surgery (fascia plication)
Description: classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
Study: NCT02347111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: flecainide up to 150mg twice daily for the control of atrial fibrillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: flecainide up to 150mg twice daily for the control of atrial fibrillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: sotalol up to 120mg twice daily for the control of atrial fibrillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: sotalol up to 120mg twice daily for the control of atrial fibrillation
Study: NCT03297099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Laparoscopic operation
Description: Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.